Absence of p21 expression is associated with abnormal p53 in human breast carcinomas

British Journal of Cancer

Volumn 76, Issue 4, 1997, Pages 480-485

  Ellis, P A ^a   Lonning, P E ^b   Borresen Dale, A ^c   Aas, T ^d   Geisler, S ^b   Akslen, L A ^d   Salter, I ^a   Smith, I E ^a   Dowsett, M ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

Breast cancer; Immunohistochemistry; p21; p53; WAF 1

Indexed keywords

DNA; DOXORUBICIN; MUTANT PROTEIN; PROTEIN P21; PROTEIN P53;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CONTROLLED STUDY; DNA SEQUENCE; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0030814105     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1997.413     Document Type: Article

References (34)

1. Aas T, Borresen A, Geisler S, Johnson H, Varhaug JK, Akslen LA and Lonning PE (1996) Specific TP53 gene mutation sare associated with de novo resistance to doxorubicin breast cancer patients. Nature Med 2: 811-814
2. Allred DC, Clark GM, Elledge RM, Fuqua SA, Brown RW, Chamness GC, Osborne CK and McGuire WL (1993) Association of p53 protein expression with tumour cell proliferation rate and clinical outcome in node negative breast cancer. J Natl Can Inst. 85: 200-206
3. Andersen T and Borresen A-L (1995) Alterations of the TP53 gene as a potential prognostic marker in breast carcinomas. Diag Mol Pathol 4: 203-211
4. Barbareschi M, Caffo O, Doglioni C, Fina P, Marchetti A, Buttita F, Leek R, Morelli L, Leonardi E, Bevilacqua G, Dalla Palma P and Harris A (1996) p21 WAF1 immunohistochemical expression in breast carcinoma: correlations with clinicopathological data, oestrogen receptor status, MIB-1 expression, p53 gene and protein alterations and relapse-free survival. Br J Cancer 74: 208-215
5. Barnes DM, Dublin EA, Fisher CJ, Levison DA and Millis RR (1993) Immunohistochemical detection of p53 protein in mammary carcinoma: An important new independent indicator of prognosis? Hum Pathol 24: 469-476
6. Borresen A-L, Hovig E, Smith-Sorensen B, Malkin D, Lystad S, Andersen TI, Nesland JM, Isselbacher KJ and Friend SH (1991) Constant denaturant gel electrophesis as a rapid screening technique for p53 mutations. Proc Natl Acad Sci USA 88: 8405-8409
7. Borresen A-L, Andersen TI, Eyfjord JE, Cornelis RS, Thorlacius S, Borg A, Johansson U, Theillet C, Scherneck S, Hartmen S, Cornelisse CJ, Hovig E and Devilee P (1995) TP53 mutations and breast cancer prognosis: Particularly poor survival rates for cases with mutations in the zinc-binding domains. Genes Chromosom Cancer 14: 71-75
8. Caffo O, Doglioni C, Veronese S, Bonzanini M, Marchetti A, Buttitta F, Fina P, Leek R, Morelli L, Dalla Parma P, Harris AL and Barbareschi M (1996) Prognostic value of p21 WAF-1 and p53 expression in breast carcinoma: An immunohistochemical study in 261 patients with long-term followup. Clin Cancer Res 2: 1591-1599
9. Dixon WJ (1985) BMDP statistical software. University of California Press: California
10. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW and Vogelstein B (1993). WAF1, a potential mediator of p53 tumour suppression. Cell 75: 817-825
11. El-Diery WS, Harper JW, O'Connor PM, Velculescu VE, Canman CE, Jackman J, Pietenpool JA, Burrell M, Hill DE, Wang Y, Winman KG, Mercer WE, Kastan MB, Kohn K, Elledge SJ, Kinzler KW and Vogelstein B (1994) WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 54: 1169-1174
12. El-Diery WS, Tokino T, Waldman T, Oliner JD, Velculescu VE, Burrell M, Hill DE, Healy E, Rees JL, Hamilton SR, Kinzler KW and Vogelstein B (1995) Topological control of p21(WAF1/CIP1) expression in normal and neoplastic tissues. Cancer Res 55: 2910-2919
13. Elbendary AA, Cirisano FD, Evans AC, Davis PL, Iglehart JD, Marks JR and Berchuck A (1996) Relationship between p21 expression and mutation of the p53 tumour suppressor gene in normal and malignant ovarian epithelial cells. Clin Cancer Res 2: 1571-1575
14. Elledge RM and Allred DC (1994) The p53 tumor suppressor gene in breast cancer. Breast Cancer Res Treat 32: 39-47
15. Greenblatt MS, Bennett WP, Hollstein M and Harris CC (1994) Mutations in the p53 tumour suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54: 4855-4878
16. Hall PA, McKee PH, Menage HD, Dover R and Lane DP (1993) High levels of p53 protein in UV irradiated normal skin. Oncogene 8: 203-207
17. Hayward JL, Carbone PP and Heudson JC (1977) Assessment of response to therapy in advanced breast cancer. Eur J Cancer 13: 89-94
18. Hsu SM, Raine L and Fanger H (1981) Use of the avidin-biotin-peroxidase complex (ABC) and unlabelled antibody (PAP) procedure. J Histochem Cytochem 29: 577-580
19. Jiang H, Lin J, Su ZZ, Collart FR, Huberman E and Fisher PB (1994) Induction of differentiation in human promyelocytic HL-60 leukaemia cells activates p21 WAF1/CIP1 expression in the absence of p53. Oncogene 9: 3397-3406
20. Johnson M, Dimitrov D, Vojta PJ, Barrett JC, Noda A, Pereira-Smith OM and Smith JR (1994) Evidence for a p53-independent pathway for upregulation of SD11/CIP1/WAF1/p21 RNA in human cells. Mol Carcinogen 11: 59-64
21. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B and Craig RW (1991) Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51: 6304-6311
22. Levine AJ, Momand J and Finlay CA (1991) The p53 tumour suppressor gene. Nature 351: 453-456
23. Lin D, Shields MT, Ullrich SJ, Appella E and Mercer WE (1992) Growth arrest induced by wild type p53 protein blocks cells prior to or near the restriction point in late G1 phase. Proc Natl Acad Sci 89: 9210-9214
24. Lowe SW (1995) Cancer therapy and p53. Curr Opin Oncol 7: 76-82
25. Lowe SW, Schmitt EM, Smith SW, Osborne BA and Jacks T (1993) p53 is required for radiation induced apoptosis in mouse thymocytes. Nature 362: 847-852
26. Michieli P, Chedid M, Lin D, Pierce JH, Mercer WE and Givol D (1994) Induction of WAF1/CIP1 by a p53 independent pathway. Cancer Res 54: 3391-3395
27. Ozcelik H, Mousses S and Andrulis IL (1995) Low levels of expression of an inhibitor of cyclin-dependent kinases (CIP1/WAF1) in primary breast carcinomas with p53 mutations. Clin Cancer Res 1: 907-912
28. Parker SB, Eichele G, Zhang P, Rawls A, Sands AT, Bradley A, Olson EN, Harper JW and Elledge SJ (1995) p53-independent expression of p21 CIP1 in muscle and other terminally differentiating cells. Science 267: 1024-1027
29. Sheikh MS, Li XS, Chen JC, Shao ZM, Ordonez JV and Fontana JA (1994) Mechanisms of regulation of WAF1/Cip1 gene expression in human breast carcinoma: role of p53-dependent and independent signal transduction pathways. Oncogene 9: 3407-3415
30. Slebos RJC, Baas IO, Clement M, Polak M, Mulder J-W, vanden Berg FM, Hamilton SR and Offerhaus GJA (1996) Clinical and pathological associations with p53 tumour-suppressor gene mutations and expression of p21 WAF1/CIP1 in colorectal carcinoma. Br J Cancer 74: 165-171
31. Steinman RA, Hoffman B, Iro A, Guillouf C, Lieberman DA and El-Houseini ME (1994) Induction of p21 (WAF1/CIP1) during differentiation. Oncogene 9: 3389-3396
32. Waldman T, Kinzler K and Vogelstein B (1995) p21 is necessary for p53-mediated G1 arrest in human cancer cells. Cancer Res 55: 5187-5190
33. Wu X, Boyle JH, Olson DC and Levine AJ (1993) The p53-mdm2 autoregulatory feedback loop. Genes Dev 7: 1126-1132
34. Zedenius J, Larsson C, Wallin G, Backdahl M, Aspenblad U, Hoog A, Borresen A-L and Auer G (1996) Alterations of p53 and expression of WAF1/p21 in human thyroid tumours. Thyroid 6: 1-9